Meta AnalysisID 7691
新型冠状病毒肺炎患者肝素诱导的血小板减少症发生率：系统评价与Meta分析
CRD42023452771
To conduct a systematic review of studies addressing the incident, significance of HIT in COVID-19-confirmed patients.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7691
- Evidence Id
- 16249
- Core Evidence Id
- 16249
- Source Meta Analysis Id
- 7685
- Herb2 Meta Analysis Id
- HBMA007685
- Crd Id
- CRD42023452771
- Title
- Incidence of Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis
- Review Question
- To conduct a systematic review of studies addressing the incident, significance of HIT in COVID-19-confirmed patients.
- Study Type Included
- Observational, Retrospective, or prospective study. Also, we will include interventional studies such as randomized or controlled trials If their information is sufficient
- Condition Being Studied
- Incidence and significance of heparin-induced thrombocytopenia in patients with COVID-19 who receive any forms of heparin for any indications. Heparin-induced thrombocytopenia (HIT) is a serious complication from heparin leading to transient thrombocytopenia accompanied by a highly prothrombotic state. As thromboprophylaxis with heparin is recommended in hospitalized patients with COVID-19, this intervention would increase the risk for HIT in patients with COVID-19 who expose to heparin. Awareness and early recognition are critical for proper management. This study aims to upgrade previous systematic review meta-analysis to characterize relevant clinical and laboratory data, outcomes, and incidence of HIT in patients with COVID-19.
- Participant
- Adult (>18 years) Hospitalized patients with a clinical diagnosis of COVID-19 (based on symptoms, laboratory, X-ray/CT) and/or laboratory confirmation who receive any forms of heparin for any indications.
- Animal
- Human Disease Modelled
- Intervention
- Therapeutic or Prophylaxis dose of all types of Heparin treatment (unfractionated or low molecular weight heparin)
- Comparator Control
- Not applicable.
- Main Outcome
- Incidence of HIT in patients with COVID-19 who encounter heparin Characteristics of patients with COVID-19 who develop heparin-induced thrombocytopenia (HIT). Measures of effect The pooled incidence of confirmed HIT
- Outcome Measure
- Additional Outcome
- None.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- COVID-19; Heparin; Humans; Incidence; Patients; Thrombocytopenia
- Contact
- Sahar Balagholi [email protected]
- Organisational Affiliation
- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. https://www.ibto.ir
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Iran
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-08-09
- Registration Date
- 2023-08-09
- Anticipated Start Date
- 2023-08-15
- Anticipated Completion Date
- 2024-08-15
- Title Cn
- 新型冠状病毒肺炎患者肝素诱导的血小板减少症发生率：系统评价与Meta分析
- Title En
- Incidence of Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis
- Bilingual Status
- complete